Cost-saving effects of olanzapine as long-term treatment for bipolar disorder

Journal of Mental Health Policy and Economics

Volumn 11, Issue 3, 2008, Pages 135-146

  Zhang, Yuting ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM; OLANZAPINE;

ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG USE; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITAL CHARGE; HUMAN; LONG TERM CARE; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; COST SAVINGS; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; LONG-TERM CARE; MALE; TREATMENT OUTCOME;

EID: 51049088607     PISSN: 10914358     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993; 50(2): 85-94.
2. Sajatovic M. Bipolar disorder: disease burden. Am J Manag Care 2005; 11(3 Suppl): S80-84.
3. Bowden CL. Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. J Clin Psychiatry 2005; 66 (Suppl 3): 12-19.
4. Bauer M. Review: lithium reduces relapse rates in people with bipolar disorder. Evid Based Ment Health 2004; 7(3): 72.
5. APA. Practice Guideline for the treatment of patients with bipolar disorder (Second Edition). American Psychiatric Association guideline, http://wwwpsychorg/psych_pract/treatg/pg/ bipolar_revisebook_indexcfm, (accessed September 28, 2006) 2002.
6. Bowden CL, Lecrubier Y, Bauer M, et al. Maintenance therapies for classic and other forms of bipolar disorder. J Affect Disord 2000; 59 (Suppl 1): S57-S67.
7. Bowden CL. New Developments in the Treatment of Bipolar Disorder. American Psychiatric Association 155th Annual Meeting, http://wwwmedscapecom/viewarticle/436383 (Accessed on 21 April 2006) 2006.
8. Lichtenberg FR. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Aff 2001; 20(5): 241-251.
9. Lichtenberg FR. Do (more and better) drugs keep people out of hospitals? Am Econ Rev 1996; 86(2): 384-388.
10. Zhang YSS. Do Newer Prescription Drugs Pay For Themselves? A Reassessment of the Evidence. Health Aff 2007; 26(3): 7.
11. Duggan M. Do new prescription drugs pay for themselves? The case of second-generation antipsychotics. J Health Econ 2005; 24(1): 1-31.
12. Frank RG, McGuire TG, Normand SL. Cost Offsets of New Medications for Treatment of Schizophrenia. Unpublished paper 2006.
13. Rosenbaum PR, Rubin DB. The Central Role of the Propensity Score in Observational Studies for Causal Effects. Biometrika 1983; 70(1): 41-55.
14. Joffe MM, Rosenbaum PR. Invited Commentary: Propensity Scores. Am J Epidemiol 1999; 150(4): 327-333.
15. Drake C. Effects of Misspecification of the Propensity Score on Estimators of Treatment Effect. Biometrics 1993; 49(4): 1231-1236.
16. Gu x, Rosenbaum PR. Comparison of multivariate matching methods: structures, distances, and algorithms. Journal of Computational and Graphical Statistics 1993; 2: 405-420.
17. Hansen B, Klopfer S. Optimal full matching and related designs via network flows. Journal of Computational and Graphical Statistics, http://wwwstatlsaumichedu/~bbh/hansenKlopfer2005pdf, (accessed September 1, 2006) 2006; 15.
18. Radley DC, Finkelstein SN, Stafford RS. Off-label Prescribing Among Office-based Physicians. Arch Int Med 2006; 166(4): 5.
19. Ho D, Imai K, King G, Stuart E. Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference. Political Analysis 2007; 15(199-236): http://gking.harvard.edu/files/abs/matchp-abs.shtml, accessed on January 21, 2008.
20. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002; 27(4): 299-309.
21. Manning WG, Basu A, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ 2005; 24(3):465-488.
22. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 1998; 17(3): 283-295.
23. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001; 20(4): 461-494.
24. Duan N. Stochastic microenvironment models for air pollution exposure. J Expo Anal Environ Epidemiol 1991; 1(2): 235-257.
25. Buntin MB, Zaslavsky AM. Too much ado about two-part models and transformation?: Comparing methods of modeling Medicare expenditures. J Health Econ 2004; 23(3): 525-542.
26. Park R. Estimation with heteroscedastic error terms. Econometrica 1966; 34: 888.
27. Terza JV, Basu A, Rathouz PJ. Two-stage residual inclusion estimation: Addressing endogeneity in health econometric modeling. J Health Econ;In Press,
28. Staiger D, Stock JH. Instrumental variables regression with weak instruments. Econometrica 1997; 63(3): 557-586.